PEL

Nicholas Piramal India Ltd. has informed the Exchange that Nandan Piramal Investments Private Limited (Nandan Piramal Investments Private Limited is part of the Promoter Group), have sold 90,00,000 shares aggregating to 4.736% of the total paid up capital of Nicholas Piramal India Limited. The date of sale is February 28, 2005 and the mode of sale is through off market. The shareholding of Nandan Piramal Investments Private Limited after the said sale is 70,77,785 shares aggregating to 3.725% of the total paid up capital of Nicholas Piramal India Limited.

Nicholas Piramal India Ltd. has informed the Exchange that Nandan Piramal Investments Private Limited (Nandan Piramal Investments Private Limited is part of the Promoter Group), have sold 62,72,171 shares aggregating to 3.301% of the total paid up capital of Nicholas Piramal India Limited. The date of sale is March 01, 2005 and the mode of sale is through off market. The shareholding of Nandan Piramal Investments Private Limited after the said sale is 805,614 shares aggregating to 0.424% of the total paid up capital of Nicholas Piramal India Limited.

Nicholas Piramal India Ltd. has informed the Exchange that the company has issued a press release dated January 21, 2005 titled 'Nicholas Piramal reports Q3-FY05 results; Sales from continuing operations up 13.8%, profit after tax up 118.2%'. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Nicholas Piramal India Ltd. has informed the Exchange that the BOD's of the Company have at the meeting held on December 17, 2004, approved the acquisition of the global Inhalation Anaesthetics (IA) business of Rhodia Organique Fine Limited (Rhodia), U.K., for a consideration of USD 14 million. This business recorded sales of USD 14 million in 2003, and gives NPIL a significant presence in the niche global IA market. This acquisition gives NPIL access to the manufacturing technology and facilities, as well as the global sales and marketing rights for two IA products - Halothane and Isofluorane

Nicholas Piramal India Ltd. has informed the Exchange that January 03, 2005 has been fixed as the Record Date for the purpose of sub-division of each of the equity shares in the share capital of the Company from face value of Rs.10/- each into 5 equity shares of face value of Rs.2/- each.

Nicholas Piramal India Ltd. had informed the Exchange that consent of the Members of the Company was being obtained by means of Postal Ballot, for the purpose of sub-division of the equity shares and unclassified shares in the share capital of the Company from face value of Rs.10/- each into 5 shares of Rs.2/- each. The Company has now informed that the results of the voting by Postal Ballot was declared on December 17, 2004 and the details of the same are as follows: 1) Postal Ballot Forms received & scrutinized : 7553; 2) No. of invalid Postal Ballot Forms : 603; 3) No. of valid Postal Ball

Nicholas Piramal India Ltd. has informed the Exchange that pursuant to Section 192A of the Companies Act, 1956, read with the Companies (passing of the resolution by postal ballot) Rules, 2001, the Company is seeking approval of the Members of the Company by Postal Ballot for the purpose of sub-division of the equity shares of Rs.10/- each as well as unissued unclassified shares of Rs.10/- each of the Company into 5 shares of Rs.2/- each commonly known as 'Share Split' and consequential alterations in the existing Clause V being Capital Clause of the Memorandum of Association and Article 3 of

Nicholas Piramal India Ltd. has informed the Exchange that the Company has shifted its registered office to the following new address w.e.f. November 03, 2004: Nicholas Piramal Tower, Peninsula Corporate Park. Gunpatrao Kadam Marg, Lower Parel, Mumbai 400013. The Contact Nos. remain the same viz, Tel. No,- 5663 666/ 5663 6551, Fax. No. 5663 6416.

Nicholas Piramal India Ltd. has informed the Exchange that the company has secured Custom Manufacturing Agreements with two leading international companies. The first is for manufacture and supply of various pharmaceutical products to a leading pharmaceuticals company ranking among the top Fortune 500 companies in the world, for sale in the US market. The second Agreement is with Allergan, Inc., USA for the manufacture of two high-value, Anti-Glucoma APIs (Active Pharmaceutical Ingredients). NPIL will cater to Allergan's worldwide requirements of Levobunolol (used in Betagan formulations) and

Nicholas Piramal India Ltd. has informed the Exchange that there has been a fire at Centre Point Building, Parel, Mumbai, on October 29, 2004 at 4.00 am, which houses one of the office premises of the Company. There has been no casualty. The details of the press release issued by the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

News Verification : The press had reports on October 28, 2004 that Nicholas Piramal India Limited expects to ink four outsourcing deals and is also in the process of setting up a finished drugs manufacturing facility at Baddi, Himachal Pradesh, at an estimated Rs. 140 crore. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Nicholas Piramal India Limited has vide its letter inter-alia stated, "The Company expects to

News Verification : The press had reports that Nicholas Piramal India Limited expects to ink four outsourcing deals and is also in the process of setting up a finished drugs manufacturing facility at Baddi, Himachal Pradesh, at an estimated Rs. 140 crore. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Reply is awaited from Nicholas Piramal India Limited.

Nicholas Piramal India Ltd. has informed the Exchange that the company and Roche Diagnostics Gmbh, Germany have mutually agreed to discontinue the agreement in terms of which Nicholas Piramal is exclusively distributing diagnostic and patient care products of Roche in India. The process and negotiations to discontinue the arrangement had commenced from early 2004 and a formal agreement to this effect has now been reached. The parties have agreed that Nicholas Piramal will cease to act as Roche's distributor in respect of the above products from January 01, 2005 when Roche Diagnostics will take

Nicholas Piramal India Ltd. has informed the Exchange that at its meeting held on October 21, 2004 the board has decided to split every equity share of face value of Rs.10/- into 5 shares of face value of Rs.2/- each, subject to requisite approval of the shareholders of the company.

Clarification of News : The press had reports that Nicholas Piramal India Ltd. might declare a bonus.The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Nicholas Piramal India Ltd. has vide its letter inter-alia stated, "We would like to inform that there is no such proposal for issue of bonus shares under consideration by the Board ".